Fungal substances as modulators of NF-κB activation pathway

Molecular Biology Reports

Volumn 34, Issue 3, 2007, Pages 145-154

  Petrova, Roumyana D ^a,b,c   Mahajna, Jamal ^b   Reznick, Abraham Z ^c   Wasser, Solomon P ^a   Denchev, Cvetomir M ^d   Nevo, Eviatar ^a  

^a UNIVERSITY OF HAIFA   (Israel)

^b MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Korea University   (South Korea)

Author keywords

Fungal substances; I B degradation; I B phosphorylation; NF B activation pathway

Indexed keywords

AMANITA MUSCARIA EXTRACT; ARMILLARIA MELLEA EXTRACT; CORDYCEPS SINENSIS EXTRACT; CYATHUS STRIATUS EXTRACT; FOMES FOMENTARIUS EXTRACT; FUNGAL PROTEIN; GANODERMA LUCIDUM EXTRACT; I KAPPA B ALPHA; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENTINUS POLYCHROUS EXTRACT; LEUCOCOPRINUS BIRNBAUMII EXTRACT; LUCIFERASE; MARASMIUS OREADES EXTRACT; OMPHALOTUS OLEARIUS EXTRACT; PANAEOLUS SUBBALTEATUS EXTRACT; PARTHENOLIDE; PHALLUS IMPUDICUS EXTRACT; PHOLIOTA AURIVELLA EXTRACT; PLEUROTUS ERYNGII EXTRACT; PLEUROTUS OSTREATUS EXTRACT; PLEUROTUS PULMONARIUS EXTRACT; SCHIZOPHYLLUM COMMUNE EXTRACT; SPARASSIS CRISPA EXTRACT; TRAMETES GIBBOSA EXTRACT; TRAMETES ZONATA EXTRACT; TRICHOLOMOPSIS SULPHUREOIDES EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; CYATHUS STRIATUS; ENZYME ACTIVATION; ENZYME INHIBITION; FUNGUS; HUMAN; HUMAN CELL; MARASMIUS OREADES; NONHUMAN; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RAT; REPORTER GENE; SCREENING;

CELL SURVIVAL; CYTOTOXINS; DRUG EVALUATION, PRECLINICAL; FUNGAL PROTEINS; FUNGI; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B PROTEINS; NF-KAPPA B; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

CYATHUS STRIATUS; MARASMIUS OREADES;

EID: 34547204040     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-006-9027-5     Document Type: Article

References (48)

1. Wasser SP, Weis AL (1999) Medicinal properties of substances occurring in higher Basidiomycetes mushrooms: current perspectives (Review). Int J Med Mushr 1:31-62
2. Wasser SP, Weis AL (1999) Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 19:65-96
3. Zaidman B, Yassin M, Mahajna J, Wasser SP (2005) Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol 67(4):453-468
4. Smith JE, Rowan NJ, Sullivan R (2002) Medicinal mushrooms: their therapeutic properties and current medical usage with special emphasis on cancer treatments. Cancer Research UK. University of Strathclyde, Glasgow
5. McMoris TC, Anchel MJ (1963) The structures of the basidiomycete metabolites illudin S and illudin M. J Am Chem Soc 85:831
6. McMoris TC, Yu J, Lira R, Dawe R, McDonald JR, Waters SJ, Estes LA, Kelner MJ (2001) Structure-activity studies of antitumor agent irofulven (hydroxymethylacylfulvene) and analogues. J Org Chem 66:6158-6163
7. Dick RA, Yu X, Kensler TW (2004) NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven. Clin Cancer Res 10(4):1492-1499
8. Jong SC, Donovick R (1989) Antitumor and antiviral substances from fungi. Adv Appl Microbiol 34:183-262
9. Wolf-Reiner A (2001) Bioactive sesquiterpenes produced by fungi: are they useful for humans as well? Curr Med Chem 8:583-606
10. Dembitsky VM, Rezanka T, Spizek J, Hanus LO (2005) Secondary metabolites of slime molds (myxomycetes). Phytochemistry 66:747-769
11. Lorenzen K, Anke T (1998) Basidiomycetes as a source for new bioactive natural products. Curr Org Chem 2:329-364
12. Smania A Jr, Monache FD, Smania EFA, Cuneo RS (1999) Antibacterial activity of steroidal compounds isolated from Ganoderma applanatum (Pers.) Pat. (Aphyllophoromycetidae) fruit body. Int J Med Mushr 1:325-330
13. Smania EFA, Monache FD, Smania A Jr, Yunes RA, Cuneo RS (2003) Antifungal activity of sterols and triterpenes isolated from Ganoderma annulare. Fitoterapia 74:375-377
14. Shiao MS (2003) Natural products of the medicinal mushroom Ganoderma lucidum: occurrence, biological activities, and pharmacological functions. Chem Rec 3:172-180
15. Sliva D (2003) Ganoderma lucidum (reishi) in cancer treatment. Inegr Cancer Ther 2(4):358-364
16. Lindequist U, Niedermeyer THJ, Julich WD (2005) The pharmacological potential of mushrooms. eCAM 2(3):285-299
17. Zjawiony JK (2004) Biologically active compounds from Aphyllophorales (Polypore) Fungi. J Nat Prod 67:300-310
18. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr (1997) Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629-3639
19. Pahl H (1999) Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18:6853-6866
20. Zandi E, Karin M (1999) Bridging the gap: composition, regulation, and physiological function of the IκB kinase complex. Mol Cell Biol 19:4547-4551
21. Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[k]B activity. Ann Rev Immunol 18:621-663
22. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301-310
23. Petrova RD, Wasser SP, Mahajna JA, Denchev CM, Nevo E (2005) Potential role of medicinal mushrooms in breast cancer treatment: current knowledge and future perspectives. Int J Med Mushr 7(1):141-156
24. Petrova RD, Wasser SP, Mahajna JA, Denchev CM, Nevo E (2005) Medicinal mushrooms: a new source for breast cancer therapeutics. Int J Med Mushr 7(2-3):445-446
25. Mattila P, Könkö K, Eurola M, Pihlava J-M, Astola J, Vahteristo L, Hietaniemi V, Kumpulainen J, Valtonen M, Piironen V (2001) Contents of vitamins, mineral elements, and some phenolic compounds in cultivated mushrooms. J Agric Food Chem 49:2343-2348
26. Nakamura T, Akiyama Y, Matsugo S, Uzuka Y, Shibata K, Kawagishi H (2003) Purification of caffeic acid as an antioxidant from submerged culture mycelia of Phellinus linteus (Berk. et Curt.) Teng (Aphyllophoromycetidae). Int J Med Mushr 5:163-167
27. Park YM, Kim IT, Park HJ, Choi JW, Park KY, Lee JD, Nam BH, Kim DG, Lee JY, Lee KT (2004) Anti-inflammatory and anti-nociceptive effects of the methanol extract of Fomes fomentarius. Biol Pharm Bull 27(10):1588-1593
28. Kis Z, Closse A, Sigg HP, Hruban L, Snatzke G (1970) Die struktur von panepoxydon und verwandten pilzmetaboliten. Helv Chim Acta 53(7):1577-1597
29. Erkel G, Anke T, Sterner O (1996) Inhibition of NF-κB activation by panepoxydone. Biochem Biophys Res Commun 226:214-221
30. Yassin M, Mahajna JA, Wasser SP (2003) Submerged cultured mycelium extracts of higher Basidiomycetes mushrooms selectively inhibit proliferation and induce differentiation of K562 human chronic myelogenous leukemia cells. Int J Med Mushr 5:261-276
31. Khan IA, Alam SS, Jabbar A (2001) Standardization of medium for the production of maximum phytotoxic activity by Fusarium oxysporum f. sp. ciceris. Pakistan J Biol Sci 4(11):1374-1376
32. Talwar GP (1974) Handbook of practical immunology. National Book Trust, New Delhi
33. Bar-Shai M, Reznick AZ (2006) Peroxynitrite induces an alternative NF-κB activation pathway in L8 rat myoblasts. Antioxid Redox Signal 8:639-652
34. Karin M, Greten FR (2005) NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev 5:749-759
35. Aggarwal BB, Sethi G, Nair A, Ichikawa H (2006) Nuclear factor-κB: a holy grail in cancer prevention and therapy. Curr Sign Transd Ther 1:25-52
36. Wasser SP (2002) Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 60:258-274
37. Watabe M, Hishikawa K, Takayanagi A, Shimizu N, Nakaki T (2004) Caffeic acid phenetyl ester induces apoptosis by inhibition of NF-κB and activation of Fas in human breast cancer MCF-7 cells. J Biol Chem 279(7):6017-6026
38. Lu Q-Y, Sartippour MR, Brooks MN, Zhang Q, Hardy M, Go VL, Li FP, Heber D (2004) Ganoderma lucidum spore extract inhibits endothelial and breast cancer cells in vitro. Oncol Rep 12:659-662
39. Tomasi S, Lohezic-Le DF, Sauleau P, Bezivin C, Boustie J (2004) Cytotoxic activity of methanol extracts from Basidiomycete mushrooms on murine cancer cell lines. Pharmazie 59(4):290-293
40. Tateno H, Goldstein IJ (2004) Partial identification of carbohydrate-binding sites of a Galalpha1,3Galbeta1,4GlcNAc-specific lectin from the mushroom Marasmius oreades by site-directed mutagenesis. Arch Biochem Biophys 427(1):101-109
41. Warner RL, Winter HC, Speyer CL, Varani J, Oldstein IJ, Murphy HS, Johnson KJ (2004) Marasmius oreades lectin induces renal thrombotic microangiopathic lesions. Exp Mol Pathol 77(2):77-84
42. Davies DG, Hodge P (2005) Biosynthesis of the allene (-)-marasin in Marasmius ramealis. Org Biomol Chem 3:1690-1693
43. Tobe Y, Yamashita D, Takahashi T, Inata M, Sato J, Kakiuchi K, Kobiro K, Odaira Y (1990) Synthesis of (±)-marasmic acid via 1-oxaspirohexane rearrangement. J Am Chem Soc 112:775-779
44. Anke T, Kupka J, Shramm G, Steglich W (1980) Antibiotics from basidiomycetes. X. Scorodonin, a new antibacterial and antifungal metabolite from Marasmius scorodonius (Fr.). Fr J Antibiot (Tokyo) 33(5):463-467
45. Allbutt AD, Ayer WA, Brodie HJ, Johri BN, Taube H (1970) Cyathin, a new antibiotic complex produced by Cyathus helenae. Can J Microbiol 17:1401-1407
46. Anke T, Oberwinkler F, Steglich W, Höfle G (1976) The striatins-new antibiotics from the basidiomycete Cyathus striatus (Huds. ex Pers.). Wild J Antibiot 30(3):221-225
47. Ayer WA, Paice MG (1976) Metabolites of the Bird's Nest Fungi. Part 4. The isolation and structure determination of cybullol, a metabolite of Cyathus bulleri Brodie. Can J Chem 54:910-916
48. Ayer WA, McCaskill RH (1981) The cybrodins, a new class of sesquiterpenes. Can J Chem 59(14):2150-2158